Tarsus Pharmaceuticals Inc

Insider sell‑off at Tarsus Pharma: COO Neervannan Seshadri offloads shares amid a 9.5% price drop, yet continues buying options—what it means for investors

Insider sell‑to‑cover activity at Tarsus Pharmaceuticals shows routine tax‑covering sales by HR chief Whitfield, not a profit‑driven exit—focus on the company’s clinical pipeline, not the shares.

Insider sell‑to‑cover activity at Tarsus Pharmaceuticals shows routine RSU tax‑cover sales—no distress signal, just executive alignment and confidence in future growth.

Insightful analysis of William J. Link’s March 16 2026 insider sales at Tarsus—shows plan‑driven, market‑rate trades, no red flag for investors.

Insider PYOTT DAVID E I’s 2026 option and RSU buy at Tarsus shows long‑term confidence amid CEO sales, signaling potential upside once clinical milestones hit.